The Clorox Company (NYSE:CLX) Position Increased by Money Concepts Capital Corp

Money Concepts Capital Corp increased its position in shares of The Clorox Company (NYSE:CLX) by 0.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,175 shares of the company’s stock after acquiring an additional 119 shares during the quarter. Money Concepts Capital Corp’s holdings in Clorox were worth $3,265,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CLX. Achmea Investment Management B.V. lifted its stake in Clorox by 263.5% in the 1st quarter. Achmea Investment Management B.V. now owns 16,810 shares of the company’s stock worth $2,475,000 after acquiring an additional 12,186 shares in the last quarter. Canvas Wealth Advisors LLC lifted its position in shares of Clorox by 178.0% in the first quarter. Canvas Wealth Advisors LLC now owns 10,171 shares of the company’s stock worth $1,445,000 after purchasing an additional 6,513 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Clorox by 26.2% during the first quarter. Diversified Trust Co now owns 9,837 shares of the company’s stock worth $1,448,000 after purchasing an additional 2,045 shares during the period. Board of the Pension Protection Fund purchased a new position in Clorox during the first quarter valued at approximately $589,000. Finally, Robeco Institutional Asset Management B.V. increased its stake in Clorox by 44.8% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 536,962 shares of the company’s stock valued at $79,068,000 after buying an additional 166,082 shares during the period. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Down 1.2%

CLX stock opened at $118.03 on Friday. The firm has a 50-day moving average price of $131.62 and a 200-day moving average price of $145.61. The Clorox Company has a 12 month low of $117.35 and a 12 month high of $171.37. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The stock has a market capitalization of $14.55 billion, a P/E ratio of 21.19, a price-to-earnings-growth ratio of 2.70 and a beta of 0.54.

Clorox (NYSE:CLX) last posted its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.71 EPS. As a group, equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently commented on CLX. Wells Fargo & Company dropped their price objective on Clorox from $145.00 to $142.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Citigroup lowered their target price on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a research note on Monday, April 14th. Jefferies Financial Group cut their target price on shares of Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research note on Thursday. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 6th. Finally, Barclays decreased their price target on shares of Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a research note on Wednesday, May 7th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. According to MarketBeat, Clorox currently has a consensus rating of “Hold” and an average price target of $149.50.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.